

What's New from Health Canada Quoi de neuf à Santé Canada

Bruce Randall

Director General / Directeur général

Medical Devices Directorate

Direction générale des instruments médicaux

December 2025

Décembre 2025

YOUR HEALTH AND SAFETY... OUR PRIORITY.



Medical Devices Directorate

Direction des instruments médicaux

Bruce Randall
Director General

**Senior Advisor/
Issues Management**
Catherine Dion

**Bureau of
Evaluation**
A/Deepak Sharma

**Bureau of ITA SAP
and Post-market**
Roxanne Lewis

**Bureau of Licensing
Services**
Colin Foster

**Bureau of Policy
and International
Programs**
A/Sally Prawdzik

**Bureau of Planning &
Operations**
Sarah Chandler

**Cardiovascular
Devices**
Kevin Day

**Investigational
Testing**
Bisi Lawuyi

Device Licensing
Serge Allard

**International
Programs**
A/Daniel Yoon

Quality Systems
Frédéric Hamelin

Digital Health Devices
Marc Lamoureux

Post-market
Emily Hollink

Regulatory Affairs
Thomas Hazle

Policy
Maggie Graham

Admin
Rita Marinelli-Salvi
Véronique Larocque

**General and
Restorative Devices**
Constance Campbell

Post-market
A/Jason DiMuzio

Regulatory Screening

Business Intelligence

**In Vitro Diagnostic
Devices**
Patrice Sarrazin

Special Access
Peggy Seely

**Musculoskeletal
Devices**
Weimin Zhao

Government of Canada Red Tape Review initiative

- On July 9th, 2025, the Government of Canada launched [an initiative](#) for departments to review regulations and propose actions to reduce red tape.
- Ministers were asked to report to the President of the Treasury Board on their organizations' progress and next steps within 60 days
 - Health Canada and the Public Health Agency of Canada's [report on red tape reduction](#) was published on Sept 8th, 2025

Medical Devices - Key initiatives

Published Guidance

Terms and conditions for
Class II to IV devices

Using standards to support
compliance with the
regulations

Machine learning – enabled
medical devices

Application type

Guidance Finalization

Health Canada IMDRF table
of contents (ToC)

Significant change

Management of
applications

Policy Development

Unique device
identification (UDI)
system

Cost Recovery Decisions By Application Type

| Application Type | Target | APR | MAY | JUN | JUL | AUG | SEPT | OCT | FYTD | 2024-2025 |
|----------------------------------|--------|--------------|--------------|---------------|---------------|--------------|--------------|---------------|--------------|---------------|
| Class II New | 15 | 98% (181) | 99% (168) | 100% (134) | 99% (107) | 99% (134) | 99% (111) | 100% (140) | 99% (975) | 99% (1539) |
| Class II Amendments | 15 | 98% (107) | 100% (82) | 95% (102) | 100% (121) | 99% (109) | 100% (75) | 100% (107) | 98% (704) | 99% (1355) |
| Class II, III & IV Private Label | 15 | 100% (57) | 100% (51) | 95% (66) | 100% (60) | 94% (67) | 100% (47) | 100% (65) | 98% (413) | 99% (577) |
| Class III | 60 | 99% (71) | 100% (47) | 99% (70) | 100% (44) | 100% (52) | 100% (43) | 100% (61) | 99% (388) | 99% (696) |
| Class IV | 75 | 100% (12) | 96% (24) | 100% (17) | 100% (24) | 100% (20) | 100% (7) | 100% (29) | 99% (133) | 100% (205) |

| | | | |
|--------|------|--------|------|
| Legend | <90% | 90-99% | 100% |
|--------|------|--------|------|


Non-Cost Recovery Performance By Application Type

| Application Type | Target | APR | MAY | JUN | JUL | AUG | SEP | OCT | FYTD | 2024-2025 |
|-------------------------------------|--------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|---------------|---------------|
| Class II (2nd, 3rd, etc, decisions) | 15 | 58% (252) | 92% (179) | 54% (164) | 56% (194) | 49% (247) | 95% (157) | 84% (148) | 67% (1340) | 50% (2471) |
| Screening Class III & IV | 15 | 91% (117) | 86% (140) | 71% (136) | 66% (115) | 73% (97) | 77% (105) | 86% (132) | 78% (842) | 68% (1312) |
| Minor changes | 7 | 98% (604) | 99% (544) | 96% (392) | 98% (722) | 81% (350) | 86% (502) | 72% (173) | 91% (3719) | 90% (5891) |
| Special Access | 3 | 89% (448) | 94% (432) | 97% (470) | 97% (393) | 95% (429) | 98% (477) | 98% (563) | 94% (3253) | 86% (4330) |
| New ITA | 30 | 90% (63) | 89% (57) | 90% (59) | 96% (51) | 94% (52) | 80% (40) | 100% (59) | 92% (381) | 96% (640) |
| ITA Modifications | 30 | 86% (44) | 95% (43) | 100% (44) | 100% (30) | 93% (21) | 100% (26) | 100% (21) | 95% (214) | 95% (422) |


Legend <80% 80-89% 90-100%

Average Market Authorization Time - Class II & PL

[Medical devices – market authorization time / Instruments médicaux - temps d'autorisation de mise en marché - wiki](#)




Average Market Authorization Time - Class III



■ Nov 27, 2024
 ■ Dec 18, 2024
 ■ Jan 9, 2025
 ■ Feb 12, 2025
 ■ Mar 17, 2025
 ■ Apr 25, 2025
 ■ May 26, 2025
 ■ Jun 6, 2025
 ■ Jul 16, 2025
 ■ Aug 27, 2025
 ■ Sep 10, 2025
 ■ Oct 8, 2025
 ■ Nov 3, 2025

Average Market Authorization Time - Class IV



Stay Informed

What's new: Medical devices

Files added to the web site are also posted here in the **What's New** section for three weeks. Once you have browsed through the entire site, all you need to do to keep current is make sure you visit this page more than once every three weeks.

Subscribe to the RSS feed

Health Canada provides RSS (Really Simple Syndication) feeds of our news releases and advisories, warnings and recalls. One of our RSS feeds brings you to up-to-date information on medical devices.

Our services

Device Advice e-learning

[Interactive learning platform](#) covering: risk classification, licensing and labelling requirements, required submission documents, licence application types, licence amendments, and management of applications, etc.

General inquiries

meddevices-instrumentsmed@hc-sc.gc.ca

General Enquiries (classification decisions, pre-submission meetings, significant change assessments, etc.)

Our services – Three meeting types

Innovation

Opportunity to engage with manufacturers of novel technologies well in advance of the application process (investigational testing or licensing).

Pre-clinical

Opportunity to present relevant data and discuss concerns and issues regarding device development strategy. Advice received at these meetings can influence the requestor's design of the investigational testing protocol.

Pre-submission

Opportunity to present relevant data and discuss the information and evidence manufacturers intend to use to support a medical device licence application.

Questions?

Bruce Randall

Director General / Directeur général

Medical Devices Directorate / Direction des instruments médicaux

Health Products and Food Branch / Direction générale des produits de santé et des aliments

Health Canada / Santé Canada

bruce.randall@hc-sc.gc.ca